Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05841030 · ClinicalTrials.gov registry record
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
A clinical trial of Depressive Disorder, Major, sponsored by Janssen Research & Development.
- Active
- Registry status
- 545
- Enrollment target
- 20
- Study locations
NCT05841030: Active study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
NCT05841030 is a study of Depressive Disorder, Major that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 545 participants, above the 232-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (135% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05841030, a study of Depressive Disorder, Major, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- 545 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment.
Primary Outcome
Distribution of participants with different demographic characteristics will be assessed.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (20)
Florida
- Flagler Hospital and Florida Center for TMS - Saint Augustine
- Center for Revitalizing Psychiatry - Sarasota
- Interventional Psychiatry of Tampa Bay - Tampa
Illinois
- University of Chicago - Chicago
- Loyola University Medical Center - Maywood
- Baber Research Group - Naperville
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Homewood
Georgia
- Atlanta Behavioral Research, LLC - Atlanta
- Psych Atlanta, P.C. - Marietta
Massachusetts
- Lumin Health - Newton
- Univeristy of Massachusetts - Worcester
Other
- Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales - Buenos Aires
- Hospital Italiano de Buenos Aires - Buenos Aires
California
- ATP Clinical Research - California City
Connecticut
- University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2026-03-13 |
What the registry record for NCT05841030 still lists
NCT05841030 is an observational study that tracks outcomes without assigning an intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, above the 232-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (135% higher).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT05841030 names 20 study sites across 12 states, led by Florida, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT05841030 about?
NCT05841030 is a clinical study titled "A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)". The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatmen...
What is the current status of trial NCT05841030?
This trial is currently active not recruiting. The enrollment target is 545 participants. The study started on 2023-04-28. Estimated completion is 2026-03-13.
What conditions does trial NCT05841030 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT05841030?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05841030?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05841030 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05841030's enrollment target sits among peer trials
545 7th of 52 higher than 45 of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
RECRUITING
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
RECRUITING · NA
-
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
RECRUITING · NA
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI